Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Lexicon Pharmaceuticals LXRX in the last three months. The following table summarizes their ...

Viatris is ponying up $25 million upfront to obtain the rights to sell Lexicon Pharmaceuticals’ SGLT1/SGLT2 heart med sotagliflozin, known commercially as Inpefa, in all global markets beyond ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), with a price target of $10.00. The company’s shares ...

Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), retaining the price target of $10.00. Joseph Pantginis has given his Buy ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Lexicon Pharmaceuticals is selling rights to its only marketed drug outside of the U.S. and Europe amid a ...

Credit: Jo Panuwat D/Shutterstock. Lexicon Pharmaceuticals has entered a licensing agreement with Viatris, granting the latter exclusive rights to commercialise sotagliflozin in all indications ...

The deal is a boost to Lexicon, because the company was unlikely to try to sell Inpefa outside of the U.S. on its own, according to Jefferies’ Tsai. Meanwhile, the drug fits into plans by Viatris to ...

PITTSBURGH, Oct. 16, 2024 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it has entered into an exclusive licensing agreement with Lexicon ...